Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce. After ...

Less than 18 months after listing on the Nasdaq, CAR-T therapy developer CARGO Therapeutics has abandoned its development efforts and slashed around 90% of its workforce. The move has come just a few ...

We're dedicated to nurturing and guiding the future generation of physicians and physician-scientists, recognizing that our trainees are the cornerstone of our nation's healthcare system.

How to unleash innovation, energy, and commitment by Herminia Ibarra and Anne Scoular Once upon a time, most people began successful careers by developing expertise in a technical, functional, or ...